Jessie Kroonen


I’m interested in SUMOylation and cancer. SUMO is as a posttranslational modifier regulating cell cycle progression. Sustained proliferative capacity is a hallmark of cancer. Inhibiting SUMO in cancer cells could reduce their proliferative capacity and SUMO inhibitors could potentially evolve as novel therapeutic option in cancer. My focus is on in vitro and in vivo capacity of SUMO activating enzyme inhibitors and their potential to halt cancer cell growth. Focussing on the mechanisms of SUMO in cell cycle progression, we are investigating several target proteins including the APC/c which is a key regulator in mitosis.

Curriculum Vitae:

I studied Molecular Nutrition and Toxicology at Wageningen University, the Netherlands. I conducted my master internship at Stony Brook University in New York, USA. At Stony Brook University I was part of the Molecular Cell Biology department and researched the role of FABPs in prostate cancer progression. Since, October 1st 2017 I work as a PhD-student in the lab of Alfred Vertegaal, investigating the role of SUMO signal transduction in cancer. 


  • Targeting SUMO Signaling to Wrestle Cancer.

    Kroonen, J. S., & Vertegaal, A. C. O.

    Trends in Cancer, 2020

  • Molecular mechanisms of APC/C release from spindle assembly checkpoint inhibition by APC/C SUMOylation.

    Yatskevich, S., Kroonen, J. S., Alfieri, C., Tischer, T., Howes, A. C., Clijsters, L., Yang, J., Zhang, Z., Yan, K., Vertegaal, A. C. O., & Barford, D.

    Cell Reports. 2021 34(13), 108929.

  • SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone.

    Kroonen, J. S., Kruisselbrink, A. B., Briaire-de Bruijn, I. H., Olaofe, O. O., Bovée, J. V. M. G., & Vertegaal, A. C. O.

    Cancers. 2021 13(15), 3823.


Collaborate with us

Looking for information on one of our topics, a new place to conduct your research or experienced research to join forces with?  Feel free to contact us.!

Read more